Anuh Pharma (506260) Q4 03/04 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 03/04 earnings summary
23 Oct, 2026Executive summary
FY04 net sales and operating income rose 50.1% YoY to Rs 535.5m; PAT increased to Rs 60.3m from Rs 38.5m.
Export sales grew 46.5% to Rs 326.5m, supported by higher turnover across manufacturing and trading.
Financial highlights
Net sales and operating income Rs 535.5m vs Rs 356.7m YoY; total income Rs 554.7m vs Rs 371.7m.
PBT Rs 83.0m vs Rs 52.3m; PAT Rs 60.3m vs Rs 38.5m, after current tax of Rs 23.1m and deferred tax credit of Rs 0.35m.
Other income Rs 19.2m, including Rs 9.9m profit on investment sales; prior-year investment-sale gain was Rs 8.9m.
Outlook and guidance
Stable market conditions; management expected satisfactory turnover and profit growth in FY05, targeting better performance through productivity initiatives and stringent cost control.
Latest events from Anuh Pharma
- Sales and exports grew as the new Tarapur API facility came on stream.506260
Q4 06/07 - Profit rose despite weaker sales; a 1:1 bonus issue and 50% dividend were proposed.506260Q4 97/98
- Profit rose despite falling sales, with export growth and deposit-compliance concerns.506260Q4 98/99
- Sales rose 50% and exports climbed to Rs 99.03m as PAT reached Rs 24.34m.506260Q4 99/00
- PAT rose to ₹39.80m as exports grew and Tarapur capacity expansion began.506260Q4 01/02
- Sales grew 11.6%, exports surged, and PAT softened; dividend rose to ₹12.50/share.506260Q4 02/03
- Profit fell amid export weakness; a new factory targets ~70% more capacity.506260Q4 04/05
- Sales rose 49.14%, PAT grew 41.57%, and the new factory came on stream.506260Q4 05/06
- FY08 sales rose 35%, PAT grew 13.29%, and 150 MT of capacity was planned.506260Q4 07/08